LGND – Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorpor

LGND

$132.72

Name : Ligand Pharmaceuticals Incorpor

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,560,726,272.00

EPSttm : -7.29

Ligand Pharmaceuticals Incorpor

$132.72

0.87%

$1.14

Float Short %

6.56

Margin Of Safety %

-33

Put/Call OI Ratio

0.51

EPS Next Q Diff

0.26

EPS Last/This Y

6.34

EPS This/Next Y

0.92

Price

132.72

Target Price

146

Analyst Recom

Performance Q

21.59

Relative Volume

1.07

Beta

0.89

Ticker: LGND

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-04	LGND	114.58	0.09	0.00	355
2025-07-07	LGND	113.93	0.09	0.00	355
2025-07-08	LGND	115.12	0.09	0.00	350
2025-07-09	LGND	122.6	0.09	0.73	362
2025-07-10	LGND	124.96	0.10	0.20	375
2025-07-11	LGND	121.62	0.09	1.00	392
2025-07-14	LGND	127.07	0.09	0.00	393
2025-07-15	LGND	124.37	0.09	0.24	394
2025-07-16	LGND	129.84	0.10	0.40	402
2025-07-17	LGND	137.84	0.10	0.39	404
2025-07-18	LGND	139.28	0.17	0.08	544
2025-07-21	LGND	140.63	0.19	0.05	508
2025-07-22	LGND	132.6	0.18	5.21	525
2025-07-23	LGND	136.39	0.49	0.00	657
2025-07-24	LGND	132.68	0.49	0.00	660
2025-07-25	LGND	135.78	0.49	0.00	660
2025-07-28	LGND	135.02	0.49	0.94	659
2025-07-29	LGND	131.46	0.52	999.99	680
2025-07-30	LGND	135.47	0.52	0.00	680
2025-07-31	LGND	132.58	0.51	0.20	695
2025-08-01	LGND	132.78	0.51	999.99	696
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-04	LGND	114.58	1.5	200.5	6.12
2025-07-07	LGND	113.76	1.5	199.8	6.12
2025-07-08	LGND	115.12	1.5	200.7	6.12
2025-07-09	LGND	122.40	1.5	203.1	6.12
2025-07-10	LGND	124.98	1.5	201.1	6.12
2025-07-11	LGND	121.70	1.5	199.9	6.12
2025-07-14	LGND	126.92	1.5	202.2	6.12
2025-07-15	LGND	124.30	1.5	199.2	6.12
2025-07-16	LGND	129.77	1.5	202.2	6.12
2025-07-17	LGND	137.57	1.5	203.0	6.12
2025-07-18	LGND	139.12	1.5	200.7	6.12
2025-07-21	LGND	140.67	1.5	200.7	6.12
2025-07-22	LGND	132.32	1.5	197.3	6.12
2025-07-23	LGND	136.21	1.5	201.5	6.12
2025-07-24	LGND	132.83	1.5	199.0	6.12
2025-07-25	LGND	135.83	1.5	201.2	6.12
2025-07-28	LGND	134.77	1.5	199.8	6.12
2025-07-29	LGND	131.58	1.5	199.0	6.12
2025-07-30	LGND	135.23	1.5	201.4	6.12
2025-07-31	LGND	131.58	1.5	198.9	6.12
2025-08-01	LGND	132.72	1.5	200.5	6.12
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-04	LGND	0.81	2.76	6.14
2025-07-07	LGND	0.81	2.75	6.14
2025-07-08	LGND	0.81	2.75	6.14
2025-07-09	LGND	0.81	2.75	6.14
2025-07-10	LGND	0.81	2.75	6.14
2025-07-11	LGND	0.62	2.75	6.32
2025-07-14	LGND	0.62	2.95	6.32
2025-07-15	LGND	0.62	2.95	6.32
2025-07-16	LGND	0.62	2.95	6.32
2025-07-17	LGND	0.62	2.95	6.32
2025-07-18	LGND	0.62	2.95	6.32
2025-07-21	LGND	0.62	2.91	6.32
2025-07-22	LGND	0.62	2.91	6.32
2025-07-23	LGND	0.62	2.91	6.32
2025-07-24	LGND	0.62	2.91	6.32
2025-07-25	LGND	0.62	2.91	6.56
2025-07-28	LGND	0.62	2.83	6.56
2025-07-29	LGND	0.62	2.83	6.56
2025-07-30	LGND	0.62	2.83	6.56
2025-07-31	LGND	0.62	2.83	6.56
2025-08-01	LGND	0.62	2.83	6.56
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

1.33

Avg. EPS Est. Current Quarter

1.42

Avg. EPS Est. Next Quarter

1.59

Insider Transactions

0.62

Institutional Transactions

2.83

Beta

0.89

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

88.42

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

7.3

Max Drawdown 5-Year %

-65.5

Target Price

146

P/E

Forward P/E

18.86

PEG

P/S

14.11

P/B

3.22

P/Free Cash Flow

50.73

EPS

-7.12

Average EPS Est. Cur. Y

6.12

EPS Next Y. (Est.)

7.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-73.07

Relative Volume

1.07

Return on Equity vs Sector %

-40.4

Return on Equity vs Industry %

-21.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

200.5

Ligand Pharmaceuticals Incorpor

Sector: Healthcare

Industry: Biotechnology

Employees: 68

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

stock quote shares LGND – Ligand Pharmaceuticals Incorporated Stock Price stock today

news today LGND – Ligand Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch LGND – Ligand Pharmaceuticals Incorporated yahoo finance google finance

stock history LGND – Ligand Pharmaceuticals Incorporated invest stock market

stock prices LGND premarket after hours

ticker LGND fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

LGND – Ligand Pharmaceuticals Incorporated

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: LGND

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y